Analytical Overview of a Life-Saving Drug: Paxlovid in the Treatment of COVID-19
DOI:
https://doi.org/10.29070/z36bns76Keywords:
Paxlovid development, Drug efficacy, Drug safety, Drug resistance potential, global accessibilityAbstract
The paper was Analytical Overview of a Life-Saving Drug: Paxlovid in the Treatment of COVID-19. The outbreak of COVID-19 triggered a global health emergency and a rapid pursuit of effective therapeutics. Paxlovid, a combination of Nirmatrelvir and Ritonavir, emerged as one of the most promising oral antiviral treatments for COVID-19, especially in high-risk patients. This comprehensive analytical overview explores the drug's development, pharmacological properties, clinical efficacy, pharmacokinetics, side effects, resistance concerns, public health significance, and implications for future pandemics. As COVID-19 continues to evolve, understanding the role and performance of Paxlovid remains crucial in global health management. This paper aims to provide a comprehensive, analytical review of Paxlovid, detailing its pharmacological structure, clinical outcomes, accessibility, and future prospects of the a qualitative, descriptive-analytical design aimed at synthesizing clinical, pharmacological, regulatory, and public health data on Paxlovid.
Downloads
References
Hammond J, et al. (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. NEJM.
Arbel R, et al. (2022). Effectiveness of Paxlovid in Reducing Severe COVID-19 Outcomes in Real-World Settings. Lancet.
U.S. FDA. (2023). Paxlovid Full Prescribing Information.
WHO. (2023). Therapeutics and COVID-19: Living Guideline.
Medicines Patent Pool. (2022). Pfizer and MPP Agreement for Generic Paxlovid Distribution.
CDC. (2022). Paxlovid: Information for Healthcare Providers.
Pfizer. (2023). Paxlovid Global Access Report.
